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The study investigated the antibacterial activity of crude extracts of C. edwardsii,
Combretum krausii, and Maytenus nemorosa as well as their interactions with selected
antibiotics against drug resistant bacterial strains. Using the rapid p-iodonitrotetrazolium
chloride colorimetric assay, minimum inhibitory concentration values of plant extracts
and antibiotics were determined. The interactions of plant extracts and antibiotics were
studied using a checkerboard method. The MICs of the plant extracts and antibiotics
were in the range of 0.037–6.25 and 0.001–2.5 mg/ml, respectively. The plant fractions
tested in the present study displayed varying levels of antibacterial activity depending on
the bacterial strains. Generally, Staphylococcus aureus was the most susceptible of the
three strains of bacteria while the other two beta-lactamase producing Gram-negative
bacteria were the most resistant. The hexane leaf extract of M. nemorosa was the
most active (MIC = 37 µg/ml) against S. aureus. Ethyl acetate leaf extract of C. krausii
was the most active against Klebsiella pneumoniae and ethyl acetate leaf extract of
C. edwardsii was the most active against Escherichia coli. Synergistic interactions were
detected in 13% of the combinations against E. coli, 27% of the combinations against
K. pneumoniae and 80% of the combinations against S. aureus. The few synergistic
interactions observed in the present study suggest that the crude extracts of the leaves of
M. nemorosa, C. edwardsii, and C. krausii could be potential sources of broad spectrum
antibiotic resistance modifying compounds.
Keywords: antibacterial activity, synergistic effects, Maytenus nemorosa, Combretum edwardsii, Combretum
krausii
INTRODUCTION
The emergence and spread of drug-resistant bacteria remains a major challenge to public health
in the treatment of bacterial infections. Due to this resistance, the clinical efficacy of current
antimicrobial agents is decreasing againstmany pathogens. Some of the commonly used antibiotics,
especially beta-lactam antibiotics are rendered infective through some resistance mechanisms
employed by drug-resistant bacteria. One of such resistance mechanisms is the hydrolysis of the
active site, beta lactam ring, of beta-lactam antibiotics by beta-lactamases, and thereby rendering
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the antibiotic ineffective. Beta-lactamases are classified into
four different classes (A, B, C, and D) based on structural
comparisons or four groups (1–4) based on hydrolytic and
inhibitor profiles (Ambler et al., 1991; Bush and Jacoby, 2010).
Class A, C, and D beta-lactamases use a serine as a nucleophile
to hydrolyze the beta-lactam bond while class B beta-lactamases
(carbapenemases) use Zn2+ to deactivate beta-lactams.
Beta-lactamases are the most significant and prevalent
mechanism of resistance to beta-lactams. Members of the
family Enterobacteriaceae commonly express plasmid-encoded
beta-lactamases (TEM and SHV) which confer resistance to
penicillins but not to expanded-spectrum cephalosporins.
TEM-1 (class A) is the most commonly encountered beta-
lactamase in Gram-negative bacteria. Up to 90% of ampicillin
resistance in E. coli is due to the production of TEM-1 (Cooksey
et al., 1990) while the most common class A beta-lactamases
found in Klebsiella are the chromosomal and plasmid-borne
SHV enzymes and the plasmid-mediated TEM enzymes (Bush,
2001). Combination therapy has over the years become one of
the most effective strategies in combating bacterial infections
caused by drug resistant pathogens. The rationale is to enhance
the activity by achievement of a synergistic effect. According
to Rasoanaivo et al. (2011), “synergy” or “potentiation” means
that the effect of the combination is greater than the sum of
the individual effects. Synergistic effects manifest in different
ways: improving bioavailability; decreasing metabolism, and
excretion of the active component; reversal of resistance; and
modulation of adverse effects (Wagner and Ulrich-Merzenich,
2009; Rasoanaivo et al., 2011). Combination therapy is becoming
a theme of infectious diseases and is increasingly being accepted
as a reducer of microbial resistance.
Medicinal plants are known to be very rich in phytochemicals
with diverse biological activities. Researchers have shown that
co-occurring compounds in medicinal plants play a role
in enhancing the bioavailability and distribution of various
phytochemicals, and reversal of resistance (Butterweck et al.,
2003; Rath et al., 2004).
Maytenus nemorosa (Eckl. & Zeyh.) Marais [Syn:
Gymnosporia nemorosa (Eckl. & Zeyh.) Szyszyl.], (Celastraceae),
is a spiny evergreen shrub or small tree with drooping branches
growing up to 5m tall. It grows on forest edges in Mpumalanga,
Swaziland, and KwaZulu-Natal, Eastern, and Western Cape.
As far as we know, there is no information on the use of
M. nemorosa in traditional medicine. However, some members
of the genus, notably Maytenus senegalensis and Maytenus
acuminate are used to treat a wide range of ailments such as
pneumonia, tuberculosis, venereal diseases, epilepsy, diarrhea,
sore throats and stomach ailments (Pooley, 1993).
The genus Combretum, a member of the plant family
Combretaceae are found mainly in tropical and subtropical
areas of Africa and Asia. Some members of the genus are used
in traditional medicine to treat a wide range of ailments that
include inflammation, infections, diabetes, malaria, bleeding and
diarrhea. Combretum krausii Hochst, commonly known as the
forest bush willow, is a medium-sized to large tree found in
Eastern South Africa, Swaziland and SouthernMozambique (Van
Wyk, 1997; Le Roux and Reynolds, 2003). It is used as local
medicine as antiseptic, antidiuretic, tonic and appetite stimulant,
to treat wounds, and eye infections (Quattrocchi, 2012). As far
as we know there is no record of ethnopharmacological use
of Combretum edwardsii Exell. Limited information exists on
the biological activities of both C. edwardsii and C. krausii.
Antiinflammatory and antioxidant activites were reported for
both Combretum species (McGaw et al., 2001; Masoko and
Eloff, 2007). A derivative of mollic acid; 1α-hydroxycycloartenoid
mollic acid α-l-arabinoside was isolated from C. edwardsii
(Rogers, 1989) while uteroactive compounds; combretastatin,
allegic acid and their derivatives were reported for C. krausii
(Brookes et al., 1999).
In line with the ethnobotanical use of C. edwardsii, C. krausii,
M. nemorosa, the present work was designed to evaluate the
antibacterial activities of C. edwardsii, C. krausii, M. nemorosa




The plant materials used in the present study were leaves
of M. nemorosa (Eckl. & Zeyh.) Marais, C. edwardsii Exell.
and C. krausii Hochst. They were collected in January, 2015
from the Botanical Garden of the University of KwaZulu-
Natal, Pietermaritzburg, South Africa. The plants were
appropriately identified by the Curator of the garden and
voucher specimens (C. edwardsii—Chukwujekwu #8 NU;
C. krausii—Chukwujekwu #9 NU;M. nemorosa—Chukwujekwu
#10 NU) were deposited in the Herbarium of the University of
KwaZulu-Natal, Pietermaritzburg.
Preparation of Plant Extracts
Plant materials were dried at 50◦C (in the dark), powdered and
stored in paper containers at ambient temperature for <24 h
prior to extraction. The oven-dried powdered leaves (30 g of
each plant) were extracted with 80% methanol (300 ml) with
sonication for 1 h and then soaked overnight. The extracts
were filtered through a Büchner funnel using Whatman No.1
filter paper, and the solvent evaporated under reduced pressure
at 30◦C. Liquid–liquid partitioning was done by dissolving the
crude extracts (M. nemorosa = 954 mg; C. edwardsii = 1070
mg; C. krausii = 983 mg) in aqueous methanol (250ml, 80%
v/v) followed by extraction with hexane three times (3× 300ml)
in a separating funnel. The hexane layers were combined and
dried under reduced pressure, and the remaining aqueous layer
was concentrated by evaporation of the methanol (MeOH)
under reduced pressure and then diluted with distilled water
to a volume of 300 ml. The aqueous residues were extracted
three times with dichloromethane (3 × 300ml) in a separating
funnel. The dichloromethane layers were combined and dried
under reduced pressure. The aqueous layer was concentrated
and diluted as described earlier and then extracted with ethyl
acetate. Finally, the aqueous fraction was first concentrated
under reduced pressure and subsequently freeze dried. The four
fractions (hexane, dichloromethane, ethyl acetate, and aqueous)
were used in the present study.
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Chemicals for Antimicrobial Assays
P-Iodonitrotetrazolium chloride (INT; Sigma-Aldrich) was used
as microbial growth indicator and Chloramphenicol (CHL),
Ampicillin (AMP), Amoxicillin (AMX), Penicillin (PEN),
Cefotaxime (CEF; Sigma-Aldrich) were used as reference
antibiotics.
Preparation of Microorganisms
The bacteria used in this study wereKlebsiella pneumoniaeATCC
700603, Escherichia coli ATCC 25218, Staphylococcus aureus
ATCC 11632. The cultures of bacteria were maintained on
Mueller Hinton Agar (MHA) slants at 4◦C throughout the study
and used as stock cultures.
Determination of Minimum Inhibitory
Concentration (MIC)
The MIC values of plant extracts and antibiotics against
the bacterial strains were determined using a rapid
p-iodonitrotetrazolium chloride (INT) colorimetric assay
(Eloff, 1998). Stock solutions of plant extracts (100 mg/ml)
and antibiotic (10 mg/ml) were prepared with absolute ethanol
and sterilized distilled water, respectively. Prior to the assay,
stock solutions (plant extracts) were subsequently diluted with
sterilized distilled water to a concentration of 12.5 mg/ml.
These (plant extracts and antibiotics) were then added to
Mueller Hinton Broth (MHB), and serially diluted 2-fold in a
96-well-microplate to a final concentration range of 3120–24
µg/ml for plant extracts and 2500–0.61 µg/ml for antibiotics.
Bacterial strains were cultured overnight at 37◦C on MHB and
adjusted to a final density of 106 cfu/ml with MHB. These were
subsequently used as inocula. One hundred microliters (100 µl)
of inoculum was added to each well. The plates were covered
with a sterile plate sealer and then incubated at 37◦C for 20 h.
Wells containing 20% aqueous ethanol, MHB and 100 µl of
inoculum served as the negative controls. The total volume in
each well was 200 µl. The MICs of samples were observed after
20 h incubation at 37◦C, and subsequent 30 min incubation after
the addition 40 µl of 0.2 mg/ml INT. Clear wells with INT after
incubation indicate inhibition of bacterial growth. Minimum
inhibitory concentration (MIC) values were recorded as the
lowest concentration of the sample that completely inhibited
bacterial growth.
Determination of In vitro Synergistic
Activity
Combinations of the plant extracts and antibiotics were tested by
the checkerboard method. For each plant extract and antibiotics
combination, fifty microliters of MHB was added in each well
of a 96-well-microplate. Fifty microliters of each plant extract
was added in row A and was 2-fold serially diluted down to
row H. Fifty microliters of appropriate dilutions of antibiotics
was added in columns with column one having the highest
concentration and column eight the lowest concentration of
antibiotics. To the 100 µl of different combinations in each of the
96-well-microplates, 100 µl of bacterial inoculum as described
earlier, was added. The final concentration of plant extract and
antibiotics in combinations ranged from 1/64 times the MIC
(1/64 × MIC) to 2 × MIC. Further, dilutions were made where
the lowest concentrations of the plant extracts and antibiotics
in combination inhibited the growth of the test organism.
Plates were incubated for 20 h. Interpretation of the data was
achieved by calculating the fractional inhibitory concentration
index (FICI) as follows:
FIC A+ FIC B.
FIC A = (MIC of sample A in combination with
antibiotics/MIC of sample A alone).
FIC B = (MIC of antibiotics A in combination with
sample/MIC of antibiotics A alone).
The results were interpreted as follows: FICI ≤ 0.5, synergistic;
0.5 < FICI < 4, no interaction; FICI ≥ 4 antagonistic (Odds,
2003).
RESULTS AND DISCUSSION
The MICs of the plant extract fractions and standard antibiotics
are shown in Table 1. The MICs of the fractions and standard
antibiotics were in the range of 37–6250 and 1–2500 µg/ml,
respectively. The plant fractions tested in the present study
displayed varying levels of antibacterial activity depending on
TABLE 1 | MICs of different fractions of Combretum edwardsii (CE),
Combretum krausii (CK), and Maytenus nemorosa (MN) and antimicrobial
agents against test organisms.
Antimicrobial agents MIC (µg/ml)
and extracts
E. coli K. pneumonia S. aureus
Ampicillin (AMP) 2500 2500 39
Amoxicillin (AMX) 2500 2500 39
Cefotaxime (CEF) 4 63 1
Chloramphenicol (CHL) 63 63 16
Penicillin (PEN) 2500 2500 39
CEH 1560 1560 390
CED 3125 1560 195
CEE 390 1560 780
CEW 3125 3125 6250
CKH 780 1560 390
CKD 780 1560 390
CKE 1560 780 390
CKW 3125 1560 1560
MNH 1560 1560 37
MND 3125 1560 49
MNE 3125 3125 98
MNW 6250 3125 6250
Values represent triplicates of two independent experiments.CEH, Hexane fraction of
Combretum edwardsii; CED, Dichloromethane fraction of Combretum edwardsii; CEE,
Ethyl acetate fraction of Combretum edwardsii; CEW, Water fraction of Combretum
edwardsii; CKH, Hexane fraction of Combretum krausii; CKD, Dichloromethane fraction
of Combretum krausii; CKE, Ethyl acetate fraction of Combretum krausii; CKW, Water
fraction of Combretum krausii; MNH, Hexane fraction of Maytenus nemorosa; MND,
Dichloromethane fraction of Maytenus nemorosa; MNE, Ethyl acetate fraction of Maytenus
nemorosa; MNW, Water fraction of Maytenus nemorosa.
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the bacterial strains (Table 1). Generally, S. aureus was the
most susceptible of the three strains of bacteria while the other
two beta-lactamase producing Gram-negative bacteria were the
most resistant. The antibacterial activity of a plant extract is
considered significant when its MIC value is below 100 µg/ml,
moderate when ≤625 µg/ml and weak when it is above 625
µg/ml (Rios and Recio, 2005; Kuete, 2010). All the fractions
of M. nemorosa, except the water fraction, showed the highest
activity against S. aureus, the hexane fraction being the most
active. The antibacterial activities of hexane, dichloromethane
and ethyl acetate fractions ofM. nemorosa against S. aureus could
be considered significant. No information on the antibacterial
activity of M. nemorosa and its phytochemical constituents in
the literature. However, many species of Maytenus are known
for their antibacterial activities and antibacterial compounds
have also been isolated and identified from many of the
species (Matu and van Staden, 2003; Lindsey et al., 2006;
De León et al., 2010). The antibacterial activities of the two
Combretum species also vary depending on the test organism.
With respect to the Combretum fractions, the dichloromethane
fraction of C. edwardsii displayed the best antibacterial activity
(MIC = 0.195 µg/ml) against S. aureus (Table 1) while its
ethyl acetate fraction showed the best activity (MIC = 390
µg/ml) against E. coli. All the fractions of C. edwardsii displayed
relatively weak activity against K. pneumoniae (Table 1) whereas
those of C. Krausii, except the water fraction, showed moderate
antibacterial activity against S. aureus and weak activity against
E. coli and K. pneumoniae (Table 1). Little or no information
exist on the antibacterial activity and phytochemical constituents
of C. edwardsii and C. krausii. Nonetheless, members of the
genus Combretum have been extensively investigated for their
antibacterial activity (Elegami et al., 2002; Fyhrquist et al., 2002;
Eloff et al., 2005; Fankam et al., 2015). Antibacterial compounds
have been isolated and identified within this genus. Martini et al.
(2004) isolated and characterized five antibacterial flavonoids
from C. erythrophyllum. Other antibacterial phytochemicals
from Combretum species include stilbenoids, and triterpenoids
(Angeh et al., 2007; Katerere et al., 2012). This is the first report
of antibacterial activity of C. edwardsii. C. krausii has previously
been investigated for antibacterial activity (Eldeen et al., 2005),
but not against drug-resistant bacteria. The MICs of the standard
antibiotics vary. Following the trends of antimicrobial activity
pattern displayed by the plant extracts fractions; the standard
antibiotics were more active against S. aureus than E. coli
and K. pneumoniae. The duo Gram-negative bacteria showed
strong resistance to ampicillin, amoxicillin, and penicillin. The
results showed the multi-drug resistant status of the two
Gram-negative bacteria. They were less resistant to cefotaxime
and chloramphenicol. Cefotaxime was the most active of all
the standard antibiotics used in the present study. The weak
antibacterial activities exhibited by the fractions and some of the
antibiotics against the two Gram-negative bacteria could be due
to themultidrug-resistant nature of the bacteria. These are Gram-
negative drug resistant bacteria that exhibit different mechanisms
of resistance to different antibiotics. Unlike Gram-positive
bacteria, the peptidoglycan layer of Gram-negative bacteria is
surrounded by a second membrane comprised of a bilayer
of phospholipids and lipopolysaccharide known as the outer
membrane. This provides an extra layer of protection for
the cell as compared to Gram-positive bacteria. It plays a
vital role in preventing the diffusion of many antibiotics into
the cell thereby preventing the drugs from reaching their
intercellular targets to confer antibiotic activity (Worthington
and Melander, 2013). The Gram-negative bacteria used in
the present study are also beta-lactamase producing bacteria.
These enzymes are located in the bacterial cell wall and they
play a significant role in conferring antibacterial resistance on
the bacterial cells by hydrolyzing many classes of antibiotics
especially the beta-lactams that target cell wall synthesis
(Worthington and Melander, 2013). The penicillin, ampicillin,
and amoxicillin used in the present study are all beta-lactam
antibiotics and they inhibit the synthesis of bacterial cell wall.
The very weak antibacterial activities of penicillin, ampicillin,
and amoxicillin observed in the present study confirmed the
multi-drug resistant profile of the two Gram-negative bacteria.
The Gram-negative bacteria displayed more resistant to beta-
lactam antibiotics than the rest of the antibiotics. Cefotaxime
is a third generation of Cephalosporins which targets the
synthesis of bacterial cell wall while chloramphenicol targets the
synthesis of protein within the bacterial cell. They both displayed
better antibacterial activity than ampicillin, amoxicillin, and
penicillin. This could be attributed to the fact that they are
not beta-lactam antibiotics and hence do not get hydrolyzed by
beta-lactamases.
Synergistic activities resulting from the combinations of
plant extracts with antibiotics are well known in the literature
(Hübsch et al., 2014; Sahu et al., 2014). In the present study,
we explored the possible synergistic effects of combinations
of fractions of C. krausii, C. edwardsii, and M. nemorosa
with selected antibiotics, respectively, against drug resistant
pathogenic bacterial strains. The MICs obtained by the
combinations of leaf extract fractions of C. edwardsii, C. krausii,
and M. nemorosa with ampicillin, amoxicillin, cefotaxime,
chloramphenicol, and penicillin, respectively, against E. coli,
K. pneumonia, and S. aureus are presented in Tables 2–4.
Plant secondary metabolites are known to possess antimicrobial
activity. However, when used in combination, they possess
the potential to either inhibit the modified target or exhibit
a synergy by blocking one or more of the targets in the
metabolic pathway thus acting as a modifier of multidrug
resistance mechanisms (Hemaiswarya et al., 2008). The E. coli
used in the present study is a Tem-1 beta-lactamase-producing
strain (Non-ESBL). There were four synergistic (FICI ≤ 0.5)
activities detected out of 30 combinations against E. coli
(Table 2). All the synergistic activities were combinations with
cefotaxime. There were 8–16-fold decreases in the MIC of
cefotaxime in all the synergistic activities detected against E.
coli. Similarly, the MICs of hexane fraction of C. edwardsii,
dichloromethane, and ethyl acetate fractions of C. krausii
and hexane fraction of M. nemorosa in combinations with
cefotaxime, respectively, that produced synergistic activities,
were lowered between 1/130 and 1/260. The best synergistic
interaction (FICI = 0.064) was the combination between ethyl
acetate fraction of C. krausii leaf extract and cefotaxime,
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TABLE 2 | Combined effects of different fractions of Combretum edwardsii, Combretum krausii, and Maytenus nemorosa with antibiotics against
drug-resistant Escherichia coli.
Combinations Individual MIC (µg/ml) Combination MIC (µg/ml) Individual FIC FIC index (FICI) Interpretation
CEH + AMP 1560/2500 24/1250 0.02/0.5 0.52 No interaction
CEE + AMP 390/2500 12/1250 0.03/0.5 0.53 No interaction
CEH + AMX 1560/2500 24/1250 0.02/0.5 0.52 No interaction
CEE + AMX 390/2500 12/2500 0.03/1 1.03 No interaction
CEH + CEF 1560/4 12/0.25 0.01/0.06 0.07 Synergistic
CEE + CEF 390/4 3/4 0.01/1 1.01 No interaction
CEH + CHL 1560/63 24/125 0.02/1.98 2.00 No interaction
CEE + CHL 309/63 50/63 0.13/1 1.13 No interaction
CEH + PEN 1560/2500 12/2500 0.01/1 1.01 No interaction
CEE + PEN 390/2500 12/2500 0.03/1 1.03 No interaction
CKH + AMP 780/2500 98/1250 0.13/0.5 0.63 No interaction
CKD + AMP 780/2500 24/1250 0.03/0.5 0.53 No interaction
CKE + AMP 1560/2500 1560/157 1/0.06 1.06 No interaction
CKH + AMX 780/2500 390/1250 0.5/0.5 1 No interaction
CKD + AMX 780/2500 49/1250 0.06/0.5 0.56 No interaction
CKE + AMX 1560/2500 1560/625 1/0.25 1.25 No interaction
CKH + CEF 780/4 390/0.5 0.5/0.13 0.63 No interaction
CKD + CEF 780/4 6/0.25 0.01/0.06 0.07 Synergistic
CKE + CEF 1560/4 6/0.25 0.004/0.06 0.064 Synergistic
CKH + CHL 780/63 780/8 1/0.13 1.13 No interaction
CKD + CHL 780/63 24/63 0.03/1 1.03 No interaction
CKE + CHL 1560/63 49/63 0.03/1 1.03 No interaction
CKH + PEN 780/2500 12/2500 0.02/1 1.02 No interaction
CKD + PEN 780/2500 12/2500 0.02/1 1.02 No interaction
CKE + PEN 1560/2500 1560/156 1/0.06 1.06 No interaction
MNH + AMP 1560/2500 409/2500 0.03/1 1.03 No interaction
MNH + AMX 1560/2500 1560/1250 1/0.5 1.5 No interaction
MNH + CEF 1560/4 195/0.25 0.13/0.06 0.19 Synergistic
MNH + CHL 1560/63 1560/8 1/0.13 1.13 Synergistic
MNH + PEN 1560/2500 12/2500 0.01/1 1.01 Synergistic
Values represent triplicates of two independent experiments.CEH, Hexane fraction of Combretum edwardsii; CEE, Ethyl acetate fraction of Combretum edwardsii; CKH, Hexane fraction
of Combretum krausii; CKD, Dichloromethane fraction of Combretum krausii; CKE, Ethyl acetate fraction of Combretum krausii; MNH, Hexane fraction of Maytenus nemorosa.
followed by hexane fraction of C. edwardsii and cefotaxime
(0.07), dichloromethane fraction of C. krausii and cefotaxime
(0.07), and hexane fraction of M. nemorosa and cefotaxime
(0.19).
A multidrug resistant strain of K. pneumoniae was used in
the present study. It is an extended-spectrum beta-lactamase
strain that produces the enzyme SHV-18. AgainstK. pneumoniae,
12 synergistic effects were detected out of 45 combinations
(Table 3).The combinations of plant extracts with cefotaxime
produced synergistic effects. The best being the combinations
of ethyl acetate fraction of C. edwardsii and cefotaxime
(FICI= 0.03), hexane fraction of C. edwardsii and cefotaxime
(FICI= 0.06), dichloromethane fraction of C. krausii and
cefotaxime (FICI = 0.06), and hexane fraction of C. krausii
and cefotaxime (FICI = 0.09). In the combination of ethyl
acetate fraction of C. edwardsii and cefotaxime, the MICs of
cefotaxime and the plant extract were lowered from 63 to
2 µg/ml (1/32 of MIC) and from 1560 to 3 µg/ml (1/520
of MIC), respectively. Synergistic effects were also observed
in the combinations of chloramphenicol with hexane fraction
of M. nemorosa (FICI = 0.14), dichloromethane fraction of
M. nemorosa (FICI = 0.38), and hexane fraction of C. krausii
(FICI= 0.38), respectively.
The most susceptible bacterial strain used in the study
was S. aureus. There were 35 synergistic effects out of 44
combinations against this strain (Table 4). Combinations with all
antibiotics, except cefotaxime, displayed synergistic activity. The
best combinations were water fraction of C. krausii and penicillin
(FICI = 0.04); ethyl acetate fraction of C. krausii and penicillin
(FICI = 0.05), hexane fraction of C. edwardsii and amoxicillin
(FICI = 0.05), hexane fraction of C. edwardsii and penicillin
(FICI = 0.06), hexane fraction of C. krausii and amoxicillin
(FICI = 0.06), and ethyl acetate of C. krausii and amoxicillin
(0.06). In the best combinations, the MICs of penicillin and
amoxicillin were reduced from 39 to 1.2µg/ml and 39 to 2µg/ml,
respectively.
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TABLE 3 | Combined effects of different fractions of Combretum edwardsii, Combretum krausii, and Maytenus nemorosa with antibiotics against
multidrug resistant Klebsiella pneumonia.
Combinations Individual MIC (µg/ml) Combination MIC (µg/ml) Individual FIC FIC index (FICI) Interpretation
CEH + AMP 1560/2500 781/157 0.5/0.06 0.56 No interaction
CED + AMP 1560/2500 49/2500 0.03/1 1.03 No interaction
CEE + AMP 1560/2500 1560/313 1/0.13 1.13 No interaction
CEH + AMX 1560/2500 24//2500 0.02/1 1.02 No interaction
CED + AMX 1560/2500 49/2500 0.03/1 1.03 No interaction
CEE + AMX 1560/2500 1560/313 1/0.13 1.13 No interaction
CEH + CEF 1560/63 3/4 0.002/0.06 0.06 Synergistic
CED + CEF 1560/63 49/8 0.03/0.12 0.15 Synergistic
CEE + CEF 1560/63 3/2 0.002/0.03 0.03 Synergistic
CEH + CHL 1560/63 24/63 0.02/1 1.02 No interaction
CED + CHL 1560/63 195/31 0.13/0.49 0.62 No interaction
CEE + CHL 1560/63 200/31 0.13/0.5 0.63 No interaction
CEH + PEN 1560/2500 12/5000 0.01/2 2.01 No interaction
CED + PEN 1560/2500 12/5000 0.01/2 2.01 No interaction
CEE + PEN 1560/2500 12/5000 0.03/2 2.03 No interaction
CKH + AMP 1560/2500 1560/157 1/0.06 1.06 No interaction
CKD + AMP 1560/2500 1560/157 1/0.06 1.06 No interaction
CKE + AMP 780/2500 0.78/157 1/0.03 1.03 No interaction
CKW + AMP 1560/2500 1560/157 1/0.06 1.06 No interaction
CKH + AMX 1560/2500 781/157 0.5/0.06 0.56 No interaction
CKD + AMX 1560/2500 781/157 0.5/0.06 0.56 No interaction
CKE + AMX 780/2500 1560/157 2/0.06 2.06 No interaction
CKW + AMX 1560/2500 1560/157 1/0.06 1.06 No interaction
CKH + CEF 1560/63 49/4 0.03/0.06 0.09 Synergistic
CKD + CEF 1560/63 3/4 0.002/0.06 0.062 Synergistic
CKE + CEF 780/63 49/4 0.06/0.06 0.12 Synergistic
CKW + CEF 1560/63 6/7.8 0.004/0.12 0.12 Synergistic
CKH + CHL 1560/63 390/8 0.25/0.13 0.38 Synergistic
CKD + CHL 1560/63 781/15.63 0.5/0.25 0.75 No interaction
CKE + CHL 780/63 1560/7.8 2/0.12 2.12 No interaction
CKW + CHL 1560/63 781/31.25 0.5/0.49 0.99 No interaction
CKH + PEN 1560/2500 12/5000 0.01/2 2.01 No interaction
CKD + PEN 1560/2500 12/5000 0.02/2 2.02 No interaction
CKE + PEN 780/2500 1560/156 2/0.06 2.06 No interaction
CKW + PEN 1560/2500 12/5000 0.01/2 2.01 No interaction
MNH + AMP 1560/2500 49/2500 0.03/1 1.03 No interaction
MND + AMP 1560/2500 48.75/2500 0.03/1 1.03 No interaction
MNH + AMX 1560/2500 1560/313 1/0.13 1.13 No interaction
MND + AMX 1560/2500 6/2500 0.004/1 1 No interaction
MNH + CEF 1560/63 6/8 0.004/0.13 0.13 Synergistic
MND + CEF 1560/63 6/8 0.004/0.13 0.13 Synergistic
MNH + CHL 1560/63 24/7.8 0.02/0.12 0.14 Synergistic
MND + CHL 1560/63 390/8 0.25/0.13 0.38 Synergistic
MNH + PEN 1560/2500 12/5000 0.01/2 2.01 No interaction
MND + EN 1560/2500 12/5000 0.01/2 2.01 No interaction
Values represent triplicates of two independent experiments. CEH, Hexane fraction of Combretum edwardsii; CED, Dichloromethane fraction of Combretum edwardsii; CEE, Ethyl
acetate fraction of Combretum edwardsii; CKH, Hexane fraction of Combretum krausii; CKD, Dichloromethane fraction of Combretum krausii; CKE, Ethyl acetate fraction of Combretum
krausii; CKW, Water fraction of Combretum krausii; MNH, Hexane fraction of Maytenus nemorosa; MND, Dichloromethane fraction of Maytenus nemorosa.
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TABLE 4 | Combined effects of different fractions of Combretum edwardsii, Combretum krausii, and Maytenus nemorosa with antibiotics against
penicillin resistant S. aureus.
Combinations Individual MIC (µg/ml) Combination MIC (µg/ml) Individual FIC FIC index (FICI) Interpretation
CEH + AMP 390/39 1.5/4.9 0.004/0.13 0.13 Synergistic
CED + AMP 195/39 1.5/4.9 0.01/0.13 0.14 Synergistic
CEE + AMP 708/39 12.2/19.5 0.02/0.25 0.27 Synergistic
CEH + AMX 396/39 1.5/2 0.004/0.05 0.05 Synergistic
CED + AMX 195/39 3.1/2.4 0.02/0.06 0.08 Synergistic
CEE + AMX 780/39 49/4.9 0.06/0.13 0.19 Synergistic
CEH + CEF 390/1 195/1 0.5/1 1.5 No interaction
CED + CEF 195/1 195/0.5 1/0.5 1.5 No interaction
CEE + CEF 780/1 780/0.1 1/0.1 1.1 No interaction
CEH + CHL 390/16 98/4 0.25/0.25 0.5 Synergistic
CED + CHL 195/16 24.5/4 0.12/0.25 0.37 Synergistic
CEE + CHL 780/16 12.2/8 0.02/0.5 0.52 No interaction
CEH + PEN 390/39 2/2 0.01/0.05 0.06 Synergistic
CED + PEN 195/39 6/2.4 0.03/0.06 0.09 Synergistic
CEE + PEN 780/39 24/1.2 0.03/0.08 0.11 Synergistic
CKH + AMP 390/39 1.5/4.9 0.004/0.13 0.13 Synergistic
CKD + AMP 390/39 97.7/9.8 0.25/0.25 0.5 Synergistic
CKE + AMP 390/39 1.5/4.9 0.004/0.13 0.13 Synergistic
CKW + AMP 1560/39 1.5/4.9 0.001/0.13 0.13 Synergistic
CKH + AMX 390/39 1.5/2.4 0.004/0.06 0.06 Synergistic
CKD + AMX 390/39 97.7/9.8 0.25/0.25 0.5 Synergistic
CKE + AMX 390/39 1.5/2.4 0.004/0.06 0.06 Synergistic
CKW + AMX 1560/39 97.5/4.9 0.06/0.13 0.19 Synergistic
CKH + CEF 390/1 195/1 0.5/1 1.5 No interaction
CKD + CEF 390/1 195/0.25 0.5/0.25 0.75 No interaction
CKE + CEF 390/1 97.70.1 0.25/0.13 0.38 Synergistic
CKW + CEF 1560/1 195/0.1 0.13/0.13 0.26 Synergistic
CKH + CHL 390/16 1.5/8 0.004/0.5 0.5 Synergistic
CKD + CHL 390/16 98/4 0.25/0.25 0.5 Synergistic
CKE + CHL 390/16 97.5/2 0.25/0.13 0.38 Synergistic
CKW + CHL 1560/16 98/4 0.06/0.25 0.31 Synergistic
CKH + PEN 390/39 6/2.4 0.02/0.06 0.08 Synergistic
CKD + PEN 390/39 1.5/2.4 0.004/0.06 0.06 Synergistic
CKE + PEN 390/39 12/0.6 0.03/0.02 0.05 Synergistic
CKW + PEN 1560/39 12/1.2 0.01/0.03 0.04 Synergistic
MNH + AMP 37/39 1.5/4.9 0.04/0.13 0.17 Synergistic
MND + AMP 49/39 18.5/1.2 0.38/0.03 0.41 Synergistic
MNE + AMP 98/39 0.4/4.9 0.004/0.13 0.13 Synergistic
MNH + AMX 37/39 1.16/10 0.03/0.25 0.28 Synergistic
MND + AMX 49/39 18.5/1.2 0.38/0.03 0.41 Synergistic
MNE + AMX 98/39 0.4/2.4 0.004/0.06 0.06 Synergistic
MNH + CEF 37/1 18.5/0.13 0.5/0.13 0.63 No interaction
MND + CEF 49/1 97.5/2 1.99/2 3.99 No interaction
MNE + CEF 98/1 195/1 1.99/1 2.99 No interaction
Values represent triplicates of two independent experiments.CEH: Hexane fraction of Combretum edwardsii; CED, Dichloromethane fraction of Combretum edwardsii; CEE, Ethyl acetate
fraction of Combretum edwardsii; CKH, Hexane fraction of Combretum krausii; CKD, Dichloromethane fraction of Combretum krausii; CKE, Ethyl acetate fraction of Combretum krausii;
CKW, Water fraction of Combretum krausii; MNH, Hexane fraction of Maytenus nemorosa; MND, Dichloromethane fraction of Maytenus nemorosa; MNE, Ethyl acetate fraction of
Maytenus nemorosa.
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Considering the number and medicinal importance of
the members of the genus Combretum, only a few reports
exist on their interaction with antibiotics with regards to
antibacterial activity. The leaf extract of C. albidum potentiated
the antibacterial activity of ceftriaxone against multidrug-
resistant Pseudomonas aeruginosa (Sahu et al., 2014). In a
separate study, the leaf extract of C. molle also enhanced the
antibacterial activities of kanamycin and streptomycin against
Gram-negative bacteria including multidrug-resistant strains
(Fankam et al., 2015).
CONCLUSIONS
It is important to note how some of the extracts in the
present study enhanced the activities of some of the clinically
ineffective antibiotics against the two multi-drug Gram-negative
bacteria. Examples are the reduction of the MICs of ampicillin
and amoxicillin by different fractions of C. edwardsii and
C. krausii. The enhancement could be through the inhibition
of beta-lactamases activity or increase in the permeability of the
antibiotics therebymaking the antibiotics more effective. In other
words, they tend to reverse the antimicrobial resistance. The
constituents of these plant extracts therefore, have the potential
to enhance and restore the activities of some clinically used
antibiotics. Since combinations confirmed that in vitro effects
may not be the same in vivo, further studies are still required,
especially extensive in vivo studies and research on the toxicity
of these combinations. As far as we know, this is the first report
on the antibacterial activity of M. nemorosa, individually and in
combination with antibiotics. We intend to follow up this study
with bioactivity guided isolation of the bioactive compounds.
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